CLCS (Cell Source) 3-1 Month Momentum %: -3.75% (As of Jul. 06, 2026)


CLCS Cell Source Inc CLCS
35 GF Score
Price $0.93
View Full Analysis

What is Cell Source 3-1 Month Momentum %?

Cell Source CLCS -3.12% 35 3-1 Month Momentum % is -3.75% as of Jul. 06, 2026. GuruFocus rates CLCS with a GF Score™ of 35/100.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-06), Cell Source's 3-1 Month Momentum % is -3.75%.

The industry rank for Cell Source's 3-1 Month Momentum % or its related term are showing as below:

CLCS's 3-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -7.23 vs CLCS: -3.75

Cell Source  (OTCPK:CLCS) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Cell Source 3-1 Month Momentum % Related Terms

CLCS vs EDSA, CTXR, ASBP: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Cell Source's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Cell Source's 3-1 Month Momentum % falls into.


CLCS
35GF Score
Cell Source Inc CLCS
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source  (OTCPK:CLCS) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -3.75% mean?
Cell Source (CLCS) has a 3-1 Month Momentum % of -3.75% as of Jul. 06, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cell Source and its competitors.
Is Cell Source's 3-1 Month Momentum % too high?
Cell Source's current 3-1 Month Momentum % is -3.75%. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's 3-1 Month Momentum % compare to EDSA and CTXR?
Cell Source's 3-1 Month Momentum % of -3.75% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cell Source and its competitors. Cell Source's current 3-1 Month Momentum % is -3.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current 3-1 Month Momentum % of -3.75%. The current 3-1 Month Momentum % is -3.75%. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Cell Source (CLCS), the current 3-1 Month Momentum % is -3.75% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93
Price